VIVO - メリディアン・バイオサイエンス （Meridian Bioscience Inc.）VIVOのニュース
Latin American Dedicated Internet Access (DIA) Services Market Report 2022: Developing and/or Strengthening Telcos'' Managed Services Portfolio to present Future Opportunities - ResearchAndMarkets.com 2022/12/19 10:34:00 Kwhen Finance
Meridian Biosciences Stock: Why I Moved On But May Go Back In (NASDAQ:VIVO) 2022/12/13 19:53:57 Seeking Alpha
Meridian Biosciences released an update saying it set the closing date for its merger on Jan. 31. Read more on this deal and implications for investors.
Meridian Bioscience stock gains after announcing Jan. 31 closing date for sale 2022/12/12 15:54:02 Seeking Alpha
Meridian Bioscience (VIVO) rose 8% after it said its planned sale to SD Biosensor, SJL Partners is expected to close on Jan
Meridian Bioscience Fiscal Q4 Revenues Fall 14 Percent, Full-Year Revenues Grow 5 Percent 2022/11/22 15:14:01 GenomeWeb
The firm''s diagnostics segment revenues climbed 14 percent year over year in fiscal Q4, while life sciences revenues were down 37 percent.
Meridian Bioscience Non-GAAP EPS of $0.21, revenue of $65.67M 2022/11/22 13:46:35 Seeking Alpha
Meridian Bioscience press release (VIVO): Q4 Non-GAAP EPS of $0.21.Revenue of $65.67M (-13.8% Y/Y).Diagnostics segment net revenues increased 14% year-over-year to $39.2…
Looking Into Meridian Bioscience''s Return On Capital Employed 2022/08/26 14:33:47 Benzinga
Meridian Bioscience (NASDAQ: VIVO ) brought in sales totaling $67.77 million during Q3 according to data provided by Benzinga Pro . However, earnings decreased 125.52%, resulting in a loss of $7.34 million. In Q2, Meridian Bioscience earned $28.75 million and total sales reached $111.23 million. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign … Full story available on Benzinga.com
Meridian Bioscience Non-GAAP EPS of $0.16 misses by $0.01, revenue of $67.8M beats by $1M (NASDAQ:VIVO) 2022/08/05 12:47:57 Seeking Alpha
Meridian Bioscience press release (VIVO): Q3 Non-GAAP EPS of $0.16 misses by $0.01.Revenue of $67.8M (+6.8% Y/Y) beats by $1M.Due to the pending transaction, Meridian will no…
Meridian Bioscience: Q3 Earnings Insights 2022/08/05 12:30:51 Benzinga
Meridian Bioscience (NASDAQ: VIVO ) reported its Q3 earnings results on Friday, August 5, 2022 at 08:00 AM. Here''s what investors need to know about the announcement. Earnings Meridian Bioscience reported in-line EPS of $0.16 versus an estimate of $0.16. Revenue … Full story available on Benzinga.com
Meridian Bioscience Misses Q3 EPS by 1c By Investing.com 2022/08/05 12:15:01 Investing.com
Meridian Bioscience Misses Q3 EPS by 1c
MERIDIAN BIOSCIENCE REPORTS THIRD QUARTER FISCAL 2022 OPERATING RESULTS 2022/08/05 12:00:00 PR Newswire
CINCINNATI, Aug. 5, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the third quarter ended June 30, 2022. Third Quarter Fiscal 2022 Highlights (Comparison to Third Quarter Fiscal 2021): Consolidated net revenues totaled $67.8 million,…
Meridian Bioscience rises 5% on boosted fiscal 2022 guidance 2022/02/04 17:13:47 Seeking Alpha
Meridian Bioscience <> rose following its Q1 results and a raised fiscal 2022 guidance.The company said net revenues in Q1 fiscal were $88.3M, only 5% below the record $92.9M in
Meridian Bioscience Q1 2022 Earnings Preview 2022/02/03 18:20:27 Seeking Alpha
Meridian Bioscience (NASDAQ:VIVO) is scheduled to announce Q1 earnings results on Friday, February 4th, before market open.The consensus EPS Estimate is $0.27 (-52.6% Y/Y) and the